Cancer Antigens in Medullary Breast Cancer
Author Information
Author(s): Božica Matković, Antonio Juretić, Giulio C. Spagnoli, Viktor Šeparović, Marija Gamulin, Robert Šeparović, Nera Šarić, Martina Bašić-Koretić, Irena Novosel, Božo Krušlin
Primary Institution: University Hospital for Tumors, Zagreb, Croatia
Hypothesis
To immunohistochemically evaluate the expression of MAGE-A1, MAGE-A, and NY-ESO-1 cancer/testis (C/T) tumor antigens in medullary breast cancer (MBC) tumor samples and to analyze it in relation to the clinicopathological features.
Conclusion
Expression of C/T antigens may represent a marker of potential prognostic relevance in MBC.
Supporting Evidence
- 33% of patients expressed MAGE-A1 and MAGE-A antigens.
- 22% of patients expressed NY-ESO-1 antigen.
- Significantly more patients died in the MAGE-A-positive group compared to the MAGE-A-negative group.
Takeaway
This study looked at special proteins in breast cancer that might help doctors understand how serious the cancer is. They found that some of these proteins are linked to worse outcomes.
Methodology
This retrospective study included samples from 49 patients with typical and atypical MBC, using standard immunohistochemistry on archival paraffin-embedded tissues.
Limitations
The study's findings need confirmation with a larger number of tumor samples due to the rarity of MBC.
Participant Demographics
Patients had a median age of 51 years, with a range from 28 to 82 years.
Statistical Information
P-Value
P=0.010 for MAGE-A, P=0.031 for MAGE-A1, P=0.004 for MAGE-A.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website